Biological medicines are far more complex and usually much bigger than chemical medicines, which
The purpose of HTA is to provide high-quality information to decision makers about the clinical e
Manufacturing biological medicines is generally more complex than the production of traditional (
There is no common European consensus on how to reward healthcare innovation.
Innovative medicines generally benefit from a certain period of intellectual property protection
The biotech industry proposes the development of shared European standards for HTAs to ensure the
Biosimilar medicines are follow-on versions of original biological medicines.
HTA should be based on an in-depth interaction to discuss specific data required in order to deci